Cortisol induction by poly ICLC: Implications for clinical trials of interferon | Zendy

Bever Christopher T. | Zendy; McFarland Henry F. | Zendy; Levy Hilton B. | Zendy; McFarlin Dale E. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Cortisol induction by poly ICLC: Implications for clinical trials of interferon

Author(s) -

Bever Christopher T.,

McFarland Henry F.,

Levy Hilton B.,

McFarlin Dale E.

Publication year - 1988

Publication title -

annals of neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.764

H-Index - 296

eISSN - 1531-8249

pISSN - 0364-5134

DOI - 10.1002/ana.410230215

Subject(s) - medicine , interferon , multiple sclerosis , hydrocortisone , clinical trial , endocrinology , randomized controlled trial , inducer , gastroenterology , immunology , biology , biochemistry , gene

Because interferon injections have recently been reported to induce cortisol in cancer patients, we retrospectively reviewed cortisol levels obtained during a preliminary trial of the interferon inducer polyriboinosinic polyribocytidylic acid in poly‐ L ‐lysine and carboxymethylcellulose (poly ICLC) in multiple sclerosis patients to determine if significant cortisol induction occurred. Analysis of data from 51 poly ICLC infusions in 6 men and 4 women showed elevated cortisol levels 4 to 16 hours after infusion, with hematological changes consistent with steroid effect. The highest cortisol levels observed were in 2 patients who improved during the treatment period, but there was no clear relationship between cortisol levels and clinical outcome in the group as a whole.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research